The Board of Rui Kang Pharmaceutical Group Investments Limited announces that, with effect immediately after the close of the Offer on 28 August 2017:Mr. Chan Ka Chung has resigned as an executive Director; Mr. Cheung Wai Kwan has resigned as an executive Director; and Mr. Yuen Chun Fai has resigned as independent non-executive Director. Mr. Liu Xiaolin, an executive Director, has been appointed as the chairman of the Board. The Board announced that, with effect immediately after the close of the Offer on 28 August 2017, Mr. Leung Pak Hou Anson ceased to be the chief executive officer of the company.

The Board announces that with effect immediately after the close of the Offer on 28 August 2017: Mr. Leung Pak Hou Anson has resigned as a member of the Remuneration Committee; Mr. Leung Ka Fai has resigned as a member of each of the Nomination Committee and Remuneration Committee; following his resignation as an executive Director, Mr. Chan Ka Chung ceased to be the chairman of the Nomination Committee and a member of the Remuneration Committee; and following his resignation as an independent non-executive Director, Mr. Yuen Chun Fai ceased to be the chairman of each of the Audit Committee and the Remuneration Committee, and a member of the Nomination Committee.